Version 2.1.1.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 5R44EY013479-03
PI Name: LEAHY, CHARLES D.
PI Email: cleahy@vistasci.com
PI Title:
Project Title: OCULAR INSERT FOR THE TREATMENT OF GLAUCOMA

Abstract: DESCRIPTION (provided by applicant): Using a unique polymer matrix, tailored to the chemistry of the drug, timolol, and molded into an ocular insert in a design compatible with the conjunctival sac, we will affect the release of drug for the treatment of glaucoma over a 30 to 90 day period. Customizing a matrix with such specific chemistry is an innovative approach to ocular inserts. The long duration of release at constant rates achieved via this approach, as evidenced by Phase I in vitro results, represents a significant advance in the field and will have implications on efforts at many companies and institutions working towards extended release of drugs in ophthalmology. In Phase II we intend to show feasibility of the insert design in humans, as well as measure drug release rates in an animal model. Concurrently, we will develop a molding process similar to that used in contact lens manufacture. Efforts will be coordinated in three key fields: material development and chemistry, design and process engineering and clinical/biological studies. The specific aims are:1. Produce ocular insert material containing 1.0 percent to 5.0 percent timolol and determine the release kinetics over this concentration range from test samples.2. Develop a cast molding, photopolymerization process and produce "small" and "medium" size inserts.3. Demonstrate the safety of the ocular insert material (non-drug loaded) utilizing both in vitro and in vivo testing.4. Determine the comfort and stability of the ocular insert (non-drug loaded) in a selected patient clinical study utilizing both the "small" and "medium" size inserts.5. Determine the in vivo release characteristics of the timolol-containing ocular insert in the rabbit model.6. Develop a business plan that will be presented to potential corporate partners to secure Phase Il funding.

Thesaurus Terms:
biomaterial development /preparation, biomaterial evaluation, drug administration rate /duration, drug delivery system, eye agent, glaucoma, implant
drug screening /evaluation, eye disorder chemotherapy, pharmacokinetics, slow release drug
clinical research, human subject, laboratory rabbit, polymerization

Institution: VISTA SCIENTIFIC, LLC
1 DUNDEE PK, STE 8B
ANDOVER, MA 01810
Fiscal Year: 2003
Department:
Project Start: 01-APR-2001
Project End: 31-AUG-2004
ICD: NATIONAL EYE INSTITUTE
IRG: ZRG1


CRISP Homepage Help for CRISP Email Us